Drug Profile
Research programme: cancer therapeutics - Advanomics
Alternative Names: Adva-R46Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Advanomics
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Canada
- 25 Jul 2016 Early research in Cancer in Canada (unspecified route)